Lupine signs a license agreement with Boehringer to develop a new cancer drug

New Delhi, September 4 () Drug manufacturer Lupine said Wednesday that he signed a licensing, development and marketing agreement with Germany-based Boehringer Ingelheim for its MEK inhibitor compound, a potential therapy for patients with difficult cancers of trying

The partners aim to develop the main Lupine MEK inhibitor compound in combination with one of Boehringer Ingelheim's innovative KRAS inhibitors for patients with gastrointestinal and pulmonary cancers, the Mumbai-based firm said in a statement.

Lupine will receive a down payment of USD 20 million (around Rs 140 million rupees) with possible total milestones of more than USD 700 million (around Rs 5,000 rupees) and royalties for product sales, he said.

With the success of our second new drug discovery program in oncology, we have left a significant mark by providing novel treatments to patients, said Lupine Managing Director Nilesh Gupta.

The company's MEK inhibitor program successfully eliminated the early clinical stages, demonstrating its capabilities to offer world-class innovation, he added.

Lupine President Novel Drug Discovery and Development (NDDD), Raj Kamboj, said the success of his second NDDD program in oncology has added to his confidence in providing a highly differentiated and better innovation in his class in India for patients worldwide.

Lupin's new MEK inhibitor license allows us to combine with our innovative KRAS inhibitors to develop new combined treatment concepts that provide more effective and lasting responses for patients with activated KRAS cancers that currently have limited treatment options available, Boehringer said. Ingelheim, head of Global Cancer Research, said Norbert Kraut.

KRAS mutations occur in one in seven of all human metastatic cancers, making it the most frequently mutated cancer-causing gene with mutation rates of more than 90 percent in pancreatic cancers, more than 40 percent. in colorectal cancers and more than 30 percent in lung adenocarcinomas.

Preclinical data have shown that the combination of new Boehringer Ingelheim KRAS inhibitors with MEK inhibitors results in increased antitumor activity based on their complementary mechanisms of action. Lupine shares on Wednesday finished 0.86 percent higher at Rs 741.50 each in the BSE. MSS RVK

comments